Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Clin Chem. 2015 Nov 19;62(1):252–261. doi: 10.1373/clinchem.2015.245860

Fig. 2. Duration of response among patients treated with crizotinib.

Fig. 2

Arrows indicate patients in complete remission (no evidence of disease). Numbers in the bar indicate ALK protein expression determined by SRM. Patients in green had positive response (progression-free survival 7–29 months), patient in purple (DH12) had partial response, and patients in orange had progressive disease while on crizotinib.